PRagmatic Evaluation of Events and Benefits of Lipid Lowering in Older Adults
About the Study
Currently Recruiting: Participants
Study Drug/Intervention: Atorvastatin 40mg or matching placebo
Study Timeline: This study is expected to conclude in December 2026.
ClinicalTrials.gov ID: NCT04262206
Objectives
- To determine if statins will reduce the occurrence of the composite of death, dementia, and persistent disability in community-dwelling older adults without cardiovascular disease (CVD) or dementia at baseline.
- To determine if statins will reduce the occurrence of the co-secondary composites of MCI or dementia and CV composite outcome.
Participation Criteria
Age 75 years or older without prior MI or stroke, without dementia, and not currently taking a statin but able to take one.
Telesite Enrollment
Participants can enroll through Duke Telesite by phone from anywhere in the country, and do not need to be a patient at a physical site. The Telesite enrollment supports both English and Spanish speaking participants from anywhere in the United States, including Puerto Rico. Call 833-385-3899 for more information about enrollment in PREVENTABLE.
Sponsor/Funding
National Institute on Aging and National Heart Lung Blood Institute (NIA/NHLBI)
Learn More
- PI: Karen Alexander, MD
- PL: Pamela Monds
- Websites: preventablecommunity.org and preventabletrial.org
- Phone: 833-385-3899